ClinicalTrials.gg
CompletedNCT04242446BE HEARD IUpdated Oct 26, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3 interventional study of Bimekizumab and Placebo in Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL. Completed at 88 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Oct 26, 2026Results publication addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
505
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
18th of 139
505 · median 45
Started
2020
with 15 others
Phase 3
24 of 161
3 open now
Registered
56th of 161
by date
Lead sponsor
6 of 161
UCB Biopharma SRL

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 18th largest by enrollment of the 139 interventional ones that give a count, is one of 16 that started in 2020, is one of 24 in phase 3, and was the 56th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Bimekizumab
  • UCB4940
  • HS
  • Hidradenitis Suppurativa
  • Acne inversa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be at least 18 years of age, at the time of signing the . If a study participant is under the local age of consent and is at least 18 years of age, written informed consent will be obtained from both the study participant and the legal representative
  • Study participants must have a diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 6 months prior to the Baseline visit
  • Study participant must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla), 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits
  • Study participant must have moderate to severe HS defined as a total of ≥5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits
  • Study participant must have had an inadequate response to a course of a systemic antibiotic for treatment of HS as assessed by the Investigator through study participant interview and review of medical history
  • A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of (WOCBP) OR
    2. A WOCBP who agrees to follow the guidance during the treatment period and for at least 20 weeks after the last dose of medicinal product (IMP)

Exclusion criteria

Exclusion Criteria:

  • Draining tunnel count of >20 at the Baseline Visit
  • Any other active skin disease or condition (eg, bacterial cellulitis, candida intertrigo, extensive condyloma) that may, in the opinion of the Investigator, interfere with the assessment of hidradenitis suppurativa (HS)
  • Study participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease (IBD)
  • Primary condition, including taking immunosuppressive therapy following an organ transplant, or has had a splenectomy
  • Female who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of medicinal product (IMP)
  • Active infection or history of certain infection(s)
  • Active tuberculosis (TB) infection, latent TB infection, high risk of exposure to TB infection, current or history of nontuberculous mycobacterium (NTM) infection
  • Concurrent . Study participants with a history of malignancy within the past 5 years prior to the Screening Visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been treated and is considered cured
  • History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
  • Known to any components of bimekizumab or comparative drugs as stated in this protocol
  • Concomitant and prior medication restrictions
  • Myocardial infarction or stroke within the 6 months prior to the Screening Visit
  • Study participant has the presence of active suicidal ideation, or positive suicide behavior using the "Screening" version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
  • Presence of moderately severe major depression or severe major depression
  • Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
505 participants (actual)

Study arms

  • Experimental
    Bimekizumab dosing regimen 1

    Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.

    Drug: Bimekizumab

  • Experimental
    Bimekizumab dosing regimen 2

    Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.

    Drug: Bimekizumab

  • Experimental
    Bimekizumab dosing regimen 3

    Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.

    Drug: Bimekizumab

  • Placebo comparator
    Placebo Group

    Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.

    Drug: Bimekizumab · Other: Placebo

Interventions

  • Subjects will receive bimekizumab at pre-specified time-points.

    Also known as: UCB4940

  • OtherPlacebo

    Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16

    HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16

    HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model.

    Time frame: Week 16

  2. Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

    The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data.

    Time frame: Baseline, Week 16

  3. Absolute Change From Baseline in Worst Skin Pain Score at Week 16

    Absolute change from Baseline in Worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model.

    Time frame: Baseline, Week 16

  4. Percentage of Participants Achieving Worst Skin Pain Response at Week 16

    Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentage of participants shown do not account for model effects using logistic regression model.

    Time frame: Week 16

  5. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up \[SFU\] period).

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

  6. Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study

    A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

  7. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported.

    Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)

07

Results

Posted Jan 9, 2025

Participant flow

The study started to enroll participants in February 2020 and concluded in February 2023.

Initial Treatment Period: Week 0-16
Participant flow — Initial Treatment Period: Week 0-16
MilestonePlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Started721442890000
Completed651272590000
Not completed717300000
Withdrew: Adverse event1570000
Withdrew: Protocol violation0220000
Withdrew: Lost to follow-up1320000
Withdrew: Consent withdrawn by subject, not due to ae46140000
Withdrew: Country relocation1000000
Withdrew: Withdrawn based to exclusion criterion0010000
Withdrew: Per sponsors request due to covid 19 pandemic0010000
Withdrew: Randomized, not treated0130000
Maintenance Treatment Period: Week 16-48
Participant flow — Maintenance Treatment Period: Week 16-48
MilestonePlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Started00065125129129
Completed000448710498
Not completed00021382531
Withdrew: Adverse event0009756
Withdrew: Lack of efficacy0001733
Withdrew: Protocol violation0001212
Withdrew: Lost to follow-up0002533
Withdrew: Consent withdrawn by subject, not due to ae0007121114
Withdrew: Subject is moving a long distance from clinic0001000
Withdrew: Study schedule too demanding, clashing with work0000100
Withdrew: Subject moved a long distance from clinic0000100
Withdrew: Subject withdrew due to custody issue & relocation0000100
Withdrew: Relocation0000100
Withdrew: Patient relocated and withdrew consent0000100
Withdrew: Patient move away0000010
Withdrew: Patient relocated last minute decision0000010
Withdrew: Needs systemic therapy incompatible with protocol0000001
Withdrew: Sponsor's decision0000001
Withdrew: Develop illness would interfere with participation0000001

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16

HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 1628.7 (18.1 to 39.3)45.3 (36.8 to 53.8)47.8 (41.8 to 53.7)
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · Regression, Logistic · p = 0.030 · Odds ratio (or): 2.000 · 97.5% CI 0.979 to 4.089
  • Placebo vs BKZ Dosing Regimen 2 · Regression, Logistic · p = 0.006 · Odds ratio (or): 2.234 · 97.5% CI 1.159 to 4.307
SecondaryPercentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16

HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 1618.4 (9.3 to 27.5)24.7 (17.3 to 32.1)33.4 (27.8 to 39.1)
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · Regression, Logistic · p = 0.350 (Nominal p-value only due to the testing hierarchy failing on the HISCR50 outcome.) · Odds ratio (or): 1.416 · 97.5% CI 0.615 to 3.260
  • Placebo vs BKZ Dosing Regimen 2 · Regression, Logistic · p = 0.021 · Odds ratio (or): 2.175 · 97.5% CI 1.021 to 4.635
SecondaryAbsolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16

The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
score on a scalePlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16-2.7 ± 0.9-5.5 ± 0.6-5.0 ± 0.4
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · ANCOVA · p = 0.002 (Nominal p-value only due to the testing hierarchy failing on the HISCR50 outcome.) · Ls mean difference: -2.574 · 97.5% CI -4.472 to -0.675
  • Placebo vs BKZ Dosing Regimen 2 · ANCOVA · p = <0.001 · Ls mean difference: -2.682 · 97.5% CI -4.394 to -0.970
SecondaryAbsolute Change From Baseline in Worst Skin Pain Score at Week 16

Absolute change from Baseline in Worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Worst Skin Pain Score at Week 16
score on a scalePlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Absolute Change From Baseline in Worst Skin Pain Score at Week 16-0.99 ± 0.38-1.56 ± 0.26-2.00 ± 0.17
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · ANCOVA · p = 0.201 (Nominal p-value only due to the testing hierarchy failing on the HISCR50 outcome.) · Ls mean difference: -0.551 · 97.5% CI -1.521 to 0.418
  • Placebo vs BKZ Dosing Regimen 2 · ANCOVA · p = 0.002 · Ls mean difference: -1.186 · 97.5% CI -2.050 to -0.322
SecondaryPercentage of Participants Achieving Worst Skin Pain Response at Week 16

Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentage of participants shown do not account for model effects using logistic regression model.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Worst Skin Pain Response at Week 16
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2
Percentage of Participants Achieving Worst Skin Pain Response at Week 1615.0 (3.6 to 26.5)22.1 (12.7 to 31.4)32.3 (25.1 to 39.5)
Statistical analysis
  • Placebo vs BKZ Dosing Regimen 1 · Regression, Logistic · p = 0.367 (Nominal p-value only due to the testing hierarchy failing on the HISCR50 outcome.) · Odds ratio (or): 1.618 · 97.5% CI 0.489 to 5.352
  • Placebo vs BKZ Dosing Regimen 2 · Regression, Logistic · p = 0.041 · Odds ratio (or): 2.757 · 97.5% CI 0.909 to 8.364
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up \[SFU\] period).

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study66.765.767.181.576.079.181.4
SecondaryPercentage of Participants With Serious Treatment-emergent Adverse Events During the Study

A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period).

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study02.82.19.28.05.47.8
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported.

Time frame:
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study
percentage of participantsPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study1.44.23.513.84.81.64.7

Adverse events

Collected over From Baseline (Day 1) until Safety Follow-Up (up to Week 71). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/72 (0%)0/72 (0%)23/72 (31.9%)
BKZ Dosing Regimen 10/143 (0%)4/143 (2.8%)52/143 (36.4%)
BKZ Dosing Regimen 20/286 (0%)6/286 (2.1%)94/286 (32.9%)
Placebo/BKZ Dosing Regimen 20/65 (0%)6/65 (9.2%)38/65 (58.5%)
BKZ Dosing Regimen 1/BKZ Dosing Regimen 10/125 (0%)10/125 (8%)63/125 (50.4%)
BKZ Dosing Regimen 2/BKZ Dosing Regimen 10/129 (0%)7/129 (5.4%)69/129 (53.5%)
BKZ Dosing Regimen 2/BKZ Dosing Regimen 21/129 (0.8%)10/129 (7.8%)63/129 (48.8%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
HidradenitisSkin and subcutaneous tissue disorders0/720/1431/2861/653/1250/1292/129
Suicidal ideationPsychiatric disorders0/721/1430/2861/651/1250/1291/129
Atrial fibrillationCardiac disorders0/720/1430/2861/650/1250/1290/129
Aphthous ulcerGastrointestinal disorders0/720/1430/2861/650/1250/1290/129
Periorbital cellulitisInfections and infestations0/720/1430/2861/650/1250/1290/129
LacerationInjury, poisoning and procedural complications0/720/1430/2861/650/1250/1290/129
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/720/1430/2861/650/1250/1290/129
Genital erythemaReproductive system and breast disorders0/720/1430/2861/650/1250/1290/129
VertigoEar and labyrinth disorders0/720/1430/2860/651/1250/1290/129
Genital candidiasisInfections and infestations0/720/1430/2860/651/1250/1290/129
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Placebo/BKZ Dosing Regimen 2BKZ Dosing Regimen 1/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 1BKZ Dosing Regimen 2/BKZ Dosing Regimen 2
HidradenitisSkin and subcutaneous tissue disorders10/7212/14318/28611/6527/12519/12917/129
Corona virus infectionInfections and infestations2/722/1439/2869/6514/12519/12918/129
DiarrhoeaGastrointestinal disorders1/7212/14318/2866/656/1255/1296/129
Oral candidiasisInfections and infestations0/722/14317/2863/6511/12510/12911/129
Back painMusculoskeletal and connective tissue disorders6/720/1437/2860/654/1251/1292/129
NasopharyngitisInfections and infestations3/727/14312/2864/656/12510/1294/129
HeadacheNervous system disorders3/728/14322/2865/654/1258/1295/129
Urinary tract infectionInfections and infestations1/724/1434/2864/653/1259/1298/129
InfluenzaInfections and infestations2/720/1433/2864/652/1252/1292/129
Psychiatric evaluation abnormalInvestigations2/727/1432/2864/654/1252/1291/129

Baseline characteristics

Baseline characteristics refer to the RS which consisted of all participants randomized into the study.

Age, Continuous
Age, Continuous(Years)PlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Total
Mean36.4 ± 12.436.3 ± 11.236.9 ± 12.436.7 ± 12.0
Age, Customized
Age, Customized(Participants)PlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Total
18 years - <65 years71143283497
65 years - <85 years1168
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Total
Female4498176318
Male2846113187
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Total
American Indian or Alaskan Native0022
Asian3328
Black8214170
Native Hawaiian or Other Pacific Islander0101
White55105233393
Other/mixed5131028
Missing1113
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBKZ Dosing Regimen 1BKZ Dosing Regimen 2Total
Hispanic or Latino4132037
Not Hispanic or Latino67131268466
Missing1012
08

Study locations

88 sites
  • Hs0003 50140
    Birmingham, Alabama 35233, United States
  • Hs0003 50175
    Phoenix, Arizona 85006, United States
  • Hs0003 50161
    Los Angeles, California 90045, United States
  • Hs0003 50220
    San Diego, California 92123, United States
  • Hs0003 50205
    North Miami Beach, Florida 33162-4708, United States
  • Hs0003 50153
    Ormond Beach, Florida 32174, United States
  • Hs0003 50141
    Tampa, Florida 33613, United States
  • Hs0003 50210
    Atlanta, Georgia 30309, United States
  • Hs0003 50280
    Watkinsville, Georgia 30677, United States
  • Hs0003 50425
    Murray, Kentucky 42071, United States
  • Hs0003 50198
    Beverly, Massachusetts 01915, United States
  • Hs0003 50146
    Boston, Massachusetts 02215, United States
  • Hs0003 50194
    Omaha, Nebraska 68144, United States
  • Hs0003 50208
    Las Vegas, Nevada 89148, United States
  • Hs0003 50137
    East Windsor, New Jersey 08520, United States
  • Hs0003 50235
    New York, New York 10003, United States
  • Hs0003 50151
    Chapel Hill, North Carolina 27516, United States
  • Hs0003 50177
    Cincinnati, Ohio 45219, United States
  • Hs0003 50138
    Columbus, Ohio 43213, United States
  • Hs0003 50204
    Tulsa, Oklahoma 74135, United States
  • Hs0003 50147
    Hershey, Pennsylvania 17033, United States
  • Hs0003 50008
    Johnston, Rhode Island 02919, United States
  • Hs0003 50180
    Providence, Rhode Island 02903, United States
  • Hs0003 50142
    Nashville, Tennessee 37215, United States
  • Hs0003 50201
    Arlington, Texas 76011, United States
  • Hs0003 50166
    Dallas, Texas 75246, United States
  • Hs0003 50149
    San Antonio, Texas 78213, United States
  • Hs0003 50270
    Seattle, Washington 98101, United States
  • Hs0003 30015
    Campbelltown, Australia
  • Hs0003 30016
    Carlton, Australia
  • Hs0003 30011
    East Melbourne, Australia
  • Hs0003 30017
    Kogarah, Australia
  • Hs0003 30012
    Woolloongabba, Australia
  • Hs0003 40004
    Brussels, Belgium
  • Hs0003 40121
    Brussels, Belgium
  • Hs0003 40002
    Leuven, Belgium
  • Hs0003 40060
    Liège, Belgium
  • Hs0003 50233
    Barrie, Canada
  • Hs0003 50190
    Richmond Hill, Canada
  • Hs0003 50192
    Saskatoon, Canada
  • Hs0003 50173
    St. John's, Canada
  • Hs0003 50133
    Surrey, Canada
  • Hs0003 40127
    Aarhus N, Denmark
  • Hs0003 40197
    Amiens, France
  • Hs0003 40342
    Angers, France
  • Hs0003 40355
    Le Mans, France
  • Hs0003 40132
    Nice, France
  • Hs0003 40318
    Rouen, France
  • Hs0003 40246
    Saint-Mandé, France
  • Hs0003 40285
    Toulon, France
  • Hs0003 40325
    Berlin, Germany
  • Hs0003 40248
    Bochum, Germany
  • Hs0003 40327
    Bonn, Germany
  • Hs0003 40288
    Darmstadt, Germany
  • Hs0003 40324
    Dresden, Germany
  • Hs0003 40249
    Kiel, Germany
  • Hs0003 40357
    Magdeburg, Germany
  • Hs0003 40174
    Mainz, Germany
  • Hs0003 40323
    München, Germany
  • Hs0003 40177
    Münster, Germany
  • Hs0003 40251
    Athens, Greece
  • Hs0003 40253
    Athens, Greece
  • Hs0003 40252
    Thessaloniki, Greece
  • Hs0003 20089
    Haifa, Israel
  • Hs0003 20088
    Tel Aviv, Israel
  • Hs0003 40261
    Catania, Italy
  • Hs0003 40257
    Roma, Italy
  • Hs0003 40263
    Roma, Italy
  • Hs0003 40258
    Rozzano, Italy
  • Hs0003 40331
    Terracina, Italy
  • Hs0003 40330
    Torino, Italy
  • Hs0003 40351
    Breda, Netherlands
  • Hs0003 40292
    Groningen, Netherlands
  • Hs0003 40264
    Rotterdam, Netherlands
  • Hs0003 40332
    Trondheim, Norway
  • Hs0003 40266
    Badalona, Spain
  • Hs0003 40294
    Las Palmas de Gran Canaria, Spain
  • Hs0003 40295
    Pontevedra, Spain
  • Hs0003 40049
    Seville, Spain
  • Hs0003 40230
    Valencia, Spain
  • Hs0003 40337
    Bern, Switzerland
  • Hs0003 40406
    Geneva, Switzerland
  • Hs0003 40053
    Ankara, Turkey (Türkiye)
  • Hs0003 40270
    Antalya, Turkey (Türkiye)
  • Hs0003 40273
    Gaziantep, Turkey (Türkiye)
  • Hs0003 40050
    Istanbul, Turkey (Türkiye)
  • Hs0003 40272
    Istanbul, Turkey (Türkiye)
  • Hs0003 40271
    Izmir, Turkey (Türkiye)
09

References and documents

Publications

  • Kirby JS, Thorlacius L, Lambert J, Ciaravino V, Rolleri R, Pansar I, Muller E, Pelligra CG, Ingram JR. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL(c)) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. Br J Dermatol. 2025 Jun 20;193(1):93-104. doi: 10.1093/bjd/ljaf067. PubMed 40172122 ↗
  • Ingram JR, Lambert J, Ciaravino V, Rolleri R, Pansar I, Peterson L, Pelligra CG, Thorlacius L. Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data. Dermatol Ther (Heidelb). 2025 May;15(5):1093-1111. doi: 10.1007/s13555-025-01346-w. Epub 2025 Mar 28. PubMed 40153232 ↗
  • Shi VY, Ingram JR, Lev-Tov H, Schneider-Burrus S, Forman S, Porter ML, Hayama K, Thorlacius L, Lambert J, Vaux T, Lukowski B, Rolleri RL, Szepietowski JC. Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II. Dermatol Ther (Heidelb). 2025 Sep;15(9):2553-2570. doi: 10.1007/s13555-025-01465-4. Epub 2025 Jul 13. PubMed 40652434 ↗
  • Ingram JR, Fujita H, Gottlieb AB, Lev-Tov H, Prens E, Sayed CJ, Shi VY, Szepietowski JC, Takahashi K, Frew JW, Lambert J, Davis L, Oh T, Rolleri R, Saintmard MH, Orenstein LAV. Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials. Pain Ther. 2025 Dec;14(6):1861-1878. doi: 10.1007/s40122-025-00779-7. Epub 2025 Oct 17. PubMed 41107641 ↗
  • Tzellos T, Giamarellos-Bourboulis EJ, van Straalen KR, Martorell A, Kirby B, Alavi A, Hayama K, Khattri S, Gulliver W, Sayed CJ, Davis L, Rolleri RL, Crater C, Pansar I, Lambert J, Zouboulis CC. Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II. J Eur Acad Dermatol Venereol. 2026 Feb 14. doi: 10.1111/jdv.70356. Online ahead of print. PubMed 41689425 ↗
  • Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. J Am Acad Dermatol. 2026 Mar;94(3):867-878. doi: 10.1016/j.jaad.2025.11.031. Epub 2025 Nov 15. PubMed 41248770 ↗
  • Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA. Drugs Real World Outcomes. 2026 Jul 29. doi: 10.1007/s40801-026-00564-8. Online ahead of print. PubMed 42525209 ↗
  • Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. J Eur Acad Dermatol Venereol. 2026 Jul 22. doi: 10.1111/jdv.70631. Online ahead of print. No abstract available. PubMed 42482599 ↗
  • Daveluy S, Gottlieb AB, Augustin M, Lev-Tov H, Szepietowski JC, Horvath B, Porter ML, Hayama K, Lambert J, Tilt N, Lukowski B, Thorlacius L. Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II. Dermatol Ther (Heidelb). 2026 Jul;16(7):3315-3329. doi: 10.1007/s13555-026-01790-2. Epub 2026 Jun 5. PubMed 42247110 ↗
  • Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024 Jun 8;403(10443):2504-2519. doi: 10.1016/S0140-6736(24)00101-6. Epub 2024 May 22. PubMed 38795716 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Apr 2022, 25 months.

Results were first posted in Jan 2025, 2 years 9 months after primary completion. A results delay was requested in Apr 2023.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 25 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2020
First posted
Jan 27, 2020
StartActual
Feb 19, 2020
Primary completionActual
Apr 7, 2022
CompletionActual
Feb 19, 2023
Results delay requested
Apr 6, 2023
Results first posted
Jan 9, 2025
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
Results publication added: Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Co… PubMed 42525209 ↗; 1 more
across 2 updates, Sep 25, 2026 – Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Publications Results publication added: Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis… PubMed 42482599 ↗
    + 1 other change: verification date
  2. Sep 25, 2026
    Publications Results publication added: Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Co… PubMed 42525209 ↗
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04242446
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Feb 19, 2020
Primary completion
Apr 7, 2022
Completion
Feb 19, 2023
Results posted
Jan 9, 2025
Last update
Oct 26, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion